Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
IMRX Stock Forecast 2025-2026
$6.16
Current Price
$398.07M
Market Cap
Buy 6
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to IMRX Price Targets
+387.0%
To High Target of $30.00
+127.3%
To Median Target of $14.00
+78.6%
To Low Target of $11.00
IMRX Price Momentum
-7.9%
1 Week Change
-8.6%
1 Month Change
+187.9%
1 Year Change
+180.0%
Year-to-Date Change
-38.9%
From 52W High of $10.08
+460.0%
From 52W Low of $1.10
📊 TOP ANALYST CALLS
Did IMRX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Immuneering is one of their latest high-conviction picks.
Latest IMRX Stock Price Targets & Analyst Predictions
Based on our analysis of 13 Wall Street analysts, IMRX has a bullish consensus with a median price target of $14.00 (ranging from $11.00 to $30.00). The overall analyst rating is N/A (N/A/10). Currently trading at $6.16, the median forecast implies a 127.3% upside. This outlook is supported by 6 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Jay Olson at Oppenheimer, projecting a 387.0% upside. Conversely, the most conservative target is provided by Ami Fadia at HC Wainwright & Co., suggesting a 78.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
IMRX Analyst Ratings
6
Buy
0
Hold
0
Sell
IMRX Price Target Range
Low
$11.00
Average
$14.00
High
$30.00
Current: $6.16
Latest IMRX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for IMRX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 13, 2025 | Chardan Capital | Geulah Livshits | Buy | Maintains | $20.00 |
| Oct 31, 2025 | Leerink Partners | Andrew Berens | Outperform | Initiates | $15.00 |
| Sep 30, 2025 | HC Wainwright & Co. | Ami Fadia | Buy | Reiterates | $11.00 |
| Sep 26, 2025 | Chardan Capital | Geulah Livshits | Buy | Maintains | $20.00 |
| Sep 25, 2025 | Oppenheimer | Jay Olson | Outperform | Maintains | $30.00 |
| Sep 15, 2025 | Needham | Ami Fadia | Buy | Maintains | $11.00 |
| Aug 26, 2025 | Needham | Ami Fadia | Buy | Reiterates | $8.00 |
| Aug 14, 2025 | Chardan Capital | Geulah Livshits | Buy | Maintains | $13.00 |
| Jun 18, 2025 | Needham | Ami Fadia | Buy | Reiterates | $9.00 |
| Jun 18, 2025 | Mizuho | Graig Suvannavejh | Outperform | Maintains | $10.00 |
| Jun 18, 2025 | Chardan Capital | Geulah Livshits | Buy | Maintains | $13.00 |
| Jun 5, 2025 | Needham | Ami Fadia | Buy | Reiterates | $9.00 |
| May 7, 2025 | Oppenheimer | Jay Olson | Outperform | Maintains | $21.00 |
| May 6, 2025 | Chardan Capital | Geulah Livshits | Buy | Maintains | $13.00 |
| Apr 10, 2025 | Needham | Ami Fadia | Buy | Reiterates | $12.00 |
| Mar 24, 2025 | Chardan Capital | Geulah Livshits | Buy | Maintains | $13.00 |
| Mar 21, 2025 | Needham | Ami Fadia | Buy | Reiterates | $12.00 |
| Feb 6, 2025 | Needham | Ami Fadia | Buy | Reiterates | $12.00 |
| Jan 13, 2025 | Needham | Ami Fadia | Buy | Reiterates | $15.00 |
| Jan 8, 2025 | Chardan Capital | Geulah Livshits | Buy | Maintains | $13.00 |
Immuneering Corporation (IMRX) Competitors
The following stocks are similar to Immuneering based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Immuneering Corporation (IMRX) Financial Data
Immuneering Corporation has a market capitalization of $398.07M with a P/E ratio of -3.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -43.8%.
Valuation Metrics
Market Cap
$398.07M
Enterprise Value
$189.60M
P/E Ratio
-3.0x
PEG Ratio
0.1x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+57.2%
Current Ratio
24.0x
Debt/Equity
1.7x
ROE
-43.8%
ROA
-25.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Immuneering Corporation (IMRX) Business Model
About Immuneering Corporation
What They Do
Develops immune-based treatments for cancer.
Business Model
The company utilizes a proprietary platform to design innovative therapeutic solutions that target the molecular basis of cancer cells, aiming to inhibit tumor growth. Immuneering generates revenue through collaborations with academic institutions and strategic partnerships, as well as potential future product sales from its pipeline of medicines.
Additional Information
Immuneering is positioned within the rapidly evolving biotechnology sector, focusing on diseases with significant unmet medical needs. Its contributions to cancer treatment methodologies demonstrate the company's potential for impactful advancements in global healthcare.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
54
CEO
Dr. Benjamin J. Zeskind M.B.A., Ph.D.
Country
United States
IPO Year
2021
Website
immuneering.comImmuneering Corporation (IMRX) Latest News & Analysis
Latest News
Wall Street Analysts See a 126.21% Upside in Immuneering (IMRX): Can the Stock Really Move This High?
14 days ago
Quick Summary
Analysts' price targets for Immuneering (IMRX) suggest a potential 126.2% upside. There is strong consensus among analysts in raising earnings estimates, indicating positive sentiment.
Why It Matters
Analysts' bullish price targets suggest significant upside potential for Immuneering, indicating heightened investor interest and possible price appreciation based on earnings estimates.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Immuneering (IMRX) has been upgraded to Zacks Rank #2 (Buy), indicating increased optimism about its earnings potential, which may positively impact the stock price.
Why It Matters
The Zacks Rank #2 upgrade signals increased confidence in Immuneering's earnings potential, likely leading to a stock price increase and attracting investor interest.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Immuneering Corporation (Nasdaq: IMRX) will present at the Piper Sandler 37th Annual Healthcare Conference in New York, featuring CEO Ben Zeskind and Dr. Igor Matushansky.
Why It Matters
Immuneering's presence at a major healthcare conference signals potential investor interest and highlights its ongoing commitment to oncology, which could influence stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Immuneering Corporation (IMRX) will hold its Q3 2025 earnings call on November 12, 2025, at 4:30 PM EST, featuring discussions on financial results and clinical case studies.
Why It Matters
Immuneering's Q3 earnings call highlights financial performance and clinical advancements, crucial for assessing growth potential and investment viability in biotech, particularly in cancer therapies.
Source: Seeking Alpha
Market Sentiment:
Neutral
Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates
28 days ago
Quick Summary
Atebimetinib combined with mGnP demonstrates an 86% overall survival rate at 9 months for first-line pancreatic cancer patients, indicating strong efficacy.
Why It Matters
An 86% overall survival rate in pancreatic cancer patients suggests potential for significant therapeutic advancements, likely boosting the stock value of the company involved and attracting investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Alto Neuroscience, Autolus Therapeutics, Ascendis Pharma, and Immuneering are set to report Q3 results, potentially exceeding market expectations.
Why It Matters
Positive Q3 results from these biotech firms may indicate strong performance and growth potential, influencing stock prices and investor sentiment in the sector.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About IMRX Stock
What is Immuneering Corporation's (IMRX) stock forecast for 2026?
Based on our analysis of 13 Wall Street analysts, Immuneering Corporation (IMRX) has a median price target of $14.00. The highest price target is $30.00 and the lowest is $11.00.
Is IMRX stock a good investment in 2026?
According to current analyst ratings, IMRX has 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $6.16. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for IMRX stock?
Wall Street analysts predict IMRX stock could reach $14.00 in the next 12 months. This represents a 127.3% increase from the current price of $6.16. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Immuneering Corporation's business model?
The company utilizes a proprietary platform to design innovative therapeutic solutions that target the molecular basis of cancer cells, aiming to inhibit tumor growth. Immuneering generates revenue through collaborations with academic institutions and strategic partnerships, as well as potential future product sales from its pipeline of medicines.
What is the highest forecasted price for IMRX Immuneering Corporation?
The highest price target for IMRX is $30.00 from Jay Olson at Oppenheimer, which represents a 387.0% increase from the current price of $6.16.
What is the lowest forecasted price for IMRX Immuneering Corporation?
The lowest price target for IMRX is $11.00 from Ami Fadia at HC Wainwright & Co., which represents a 78.6% increase from the current price of $6.16.
What is the overall IMRX consensus from analysts for Immuneering Corporation?
The overall analyst consensus for IMRX is bullish. Out of 13 Wall Street analysts, 6 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $14.00.
How accurate are IMRX stock price projections?
Stock price projections, including those for Immuneering Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 11, 2025 3:09 AM UTC